A new publication involving retatrutide appeared on September 16, 2026. The paper, titled "Sustained weight loss exceeding 100 kg with sequential incretin-based therapy in Prader-Willi syndrome," was published in JCEM Case Reports.
The publication is listed under PubMed ID 42751099. It is categorized as a case report describing sequential incretin-based therapy in the context of Prader-Willi syndrome.
No specific findings, outcomes, or efficacy data from the case report are detailed here beyond the title and publication venue. This brief reports only that the publication exists and where it appeared, without summarizing or interpreting its contents.
Retatrutide remains an approved compound, and this publication represents a new addition to the literature referencing it. Readers interested in the full details of the case report should consult the original source directly through the journal or PubMed listing.
For general background on retatrutide, including its regulatory status and prior context, readers can consult the compound overview.